近日，上海交通大学药学院贾伟教授等撰写的学术论文——Gut microbiota：a potential new territory for drug targeting发表于国际著名学术期刊《自然—药物开发评论》（Nature Reviews Drug Discovery，NRDD）上。NRDD作为Nature 杂志子刊物，是国际药学领域顶级学术期刊之一。目前该杂志的影响因子为20.97。
作者在该文中从系统生物学的角度阐释了肠道微生态系统作为潜在的药物治疗靶点的可能性，并重点提出了基于肠道菌群的药物治疗策略和可能的干预模式。
在生命科学中，肠道菌群一直被认为广泛地参与了宿主营养吸收、肠道与免疫系统的发育等重要的生理过程，其变化与多种疾病的发生、发展和转归密切相关。然而，极其复杂的肠道微生态系统与研究技术手段的局限性，始终束缚着人类对肠道微生态系统的认识。近年来，不断发展的各种组学技术，如代谢组学、元基因组学与分子生物学技术等一起为揭开肠道菌群的神秘面纱提供了可能的技术支撑。上海交通大学药学院和系统生物医学研究院采用代谢组学和元基因组学，开展系统生物学研究近年来在国际上非常活跃。该论文的发表将在代谢性疾病发病机制、药理学、天然产物活性评价等学术领域产生深远的影响。
生物谷推荐原始出处：
Nature Reviews Drug Discovery 7, 123-129 (February 2008) | doi:10.1038/nrd2505
Opinion: Gut microbiota: a potential new territory for drug targeting
Wei Jia1, Houkai Li1, Liping Zhao1 & Jeremy K. Nicholson2 About the authors
Abstract
The significant involvement of the gut microbiota in human health and disease suggests that manipulation of commensal microbial composition through combinations of antibiotics, probiotics and prebiotics could be a novel therapeutic approach. A systems perspective is needed to help understand the complex host–bacteria interactions and their association with pathophysiological phenotypes so that alterations in the composition of the gut microbiota in disease states can be reversed. In this article, we describe the therapeutic rationale and potential for targeting the gut microbiota, and discuss strategies and systems-oriented technologies for achieving this goal.
Author affiliations
Wei Jia, Haukai Li and Liping Zhao are at the School of Pharmacy and at the Institute for Systems Biomedicine, Shanghai Jiao Tong University, Shanghai 200240, People's Republic of China.
Jeremy K. Nicholson is at the Department of Biomolecular Medicine, Division of Surgery Oncology Reproductive Biology and Anaesthetics, Faculty of Medicine, Imperial College London, London SW7 2AZ, UK
Correspondence to: Wei Jia1 Email: weijia@sjtu.edu.cn.
